Amryt Pharma

Investor event takeaways

  • Sectors : Pharma and healthcare
  • Companies : Amryt Pharma

Ratings and price correct at time of issue.

  • Amryt Pharma

    Closing Price: 205.0p

  • RATING 14/09/17

  • PREVIOUS RATING N/A

DAVY VIEW

Amryt’s investor event yesterday (November 3rd) covered three main areas: (1) the Filsuvez phase III data; (2) regulatory timelines; (3) commercial plans. The Filsuvez data reinforce our view that it looks compelling from a regulatory and commercial standpoint. Regulatory timelines and commercial plans outlined were broadly as expected, with additional detail provided on future launches into markets outside the US and Europe. Furthermore, Amryt’s market assumptions suggest that there could be upside to our estimates.

Download full report with analyst certification and important disclosures

Nov 4 2020, 07:25 GMT

Download